Reuters exclusively reported that U.S. drugmaker Eli Lilly LLY.N expects to launch Mounjaro, its blockbuster diabetes drug and wildly popular obesity treatment, in India as early as next year after it clears an ongoing regulatory review.
Related stories
Exclusives | Asia
Read more
India to ditch privatisation plans, pour billions in state-run firms, sources say
27 January 2025
News First | Americas
Read more
Meta warns India antitrust ruling could force roll back of features, hurt business
15 January 2025
Exclusives | Asia
Read more